Yes it is on the up after the crazy overselling |
Momentum changing here now.. |
I think it will climb back to £18 by Christmas |
US. UK price target £9.Joking but.. it feels that way with this stock sometimes.. |
US or UK listing? |
Berenberg cuts target price to 1600p from 1820p |
Now going down so it should show thumbs down ? |
Every year I wonder why they don't do tomorrow the other way round??
Good luck all 👍🏻 |
United States stock markets will be closed on Thursday, Nov. 28 and will close early on Friday, Nov. 29 in observance of the Thanksgiving holiday. |
Took advantage of the dip this afternoon and decided to increase my holding a bit. I can't see this not doing well and the dividend is good |
And there's more ......
GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial groups A, C, W, and Y. |
I assume we are talking about the US listing share price |
I preferred the 2610p ..........;0) |
Bernstein cuts target price to 2355p from 2610p |
That's what I thought , but no impact on today |
Nice late trades |
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
· Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7
· If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
· Sixth major regulatory filing acceptance this year for belantamab mafodotin combinations in this indication |
No rush await the inevitable dip. |
More good news ....
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
· First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions
· RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death.
· 35 countries, including the US, have expanded approval for GSK's RSV vaccine in this at increased risk population |
Have added more just now.
It is my opinion that the reason the economy is in such dire straits is primarily because our esteemed fund managers are a complete and utter bunch of nimrods.
This is a buy but wtfdIk |
1820 to 1300 wow!At what point is the doom and gloom priced in? Obviously sentiment is low but as we all should know.... things can quickly turn. I am holding firm and just topped up earlier this week. There are always 2 sides to a coin |
Target 600 pence ! |
Not a good sector to be invested in at the moment.Another class action initiated. This time against J&J.Never ending gravy train for greedy lawyers. |
Next stop 12 quid. |
Yep I didn't bet the house on it. Just topped up as this level seems attractive and good support. Oversold imo but who knows. Buy and hold. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
